BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Par Pharmaceutical Companies, Inc. (PRX) Begins Shipment of Generic Atacand®


5/22/2013 10:19:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WOODCLIFF LAKE, N.J., May 22, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized generic version of AstraZeneca's Atacand® (candesartan cilexetil). Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets. According to IMS Health data, annual U.S. sales of Atacand® are approximately $113 million.

Important Information About Candesartan Cilexetil Tablets

Candesartan cilexetil is an angiotensin II receptor blocker indicated for the treatment of hypertension in adults and children 1 to < 17 years of age and the treatment of heart failure (NYHA class II-IV). Candesartan cilexetil reduces cardiovascular death and heart failure hospitalization.

Candesartan cilexetil is contraindicated in patients who are hypersensitive to any component of the product. A black box warning is associated with this product regarding fetal toxicity. When pregnancy is detected, candesartan cilexetil should be discontinued as soon as possible. Drugs that act directly on the rennin-angiotensin system can cause injury and death to the developing fetus. Refer to full prescribing information for complete boxed warnings.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.

SOURCE Par Pharmaceutical Companies, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES